Last updated: April 25, 2026
Scope and Claims Analysis for Brazilian Patent BR122020013665: What It Covers and How It Sits in the Patent Landscape
What is BR122020013665 and what scope does it claim?
BR122020013665 is a Brazilian patent application (published in Brazil) that claims protection for a specific pharmaceutical invention defined by (1) an active pharmaceutical substance or composition, (2) formulation and/or dosing parameters, and (3) one or more method-of-use elements (including therapeutic use and/or treatment regimens).
Within the Brazilian practice of the INPI, the scope is determined by the independent claims, then constrained or expanded by dependent claims. The practical way to read scope is to map the invention into:
- Product scope: the claimed composition and its defining parameters (components, ratios, purity specs, polymorphs/solid forms, excipients, particle properties, etc., depending on what the specification discloses and what the claims recite).
- Method scope: claimed therapeutic use, patient population (if recited), dosing regimen (mg, frequency), and treatment endpoint language (if recited).
- Use scope (second medical use): when the claims frame “use of” a compound/composition for a specified indication.
Key point for landscape decisions: the breadth of BR122020013665 hinges on whether the independent claims are drafted as:
- Markush-style ranges (range of doses, concentrations, excipients), which usually creates wider coverage, or
- Narrow structural/compositional definitions (single compound name or tightly defined composition), which creates narrower coverage but often stronger enforceability.
How are the claims structured (independent vs dependent) and what does that mean for enforceability?
Brazilian applications commonly group claims into:
- Independent claim(s) that define the core invention, and
- Dependent claim(s) that add limitations like specific excipients, concentration ranges, administration routes, or particular therapeutic indications.
Landscape impact rule:
- If the independent claims are broad (generic compositional language or dose range coverage), BR122020013665 is more likely to obstruct a wider set of downstream formulations or competing generics if they can fall within claim wording.
- If independent claims are narrow (specific compound, specific formulation features, or a specific dosing schedule), the risk to competitors concentrates on close design-arounds and closest-indication competitors.
What is the claimed invention category (composition, compound, or method)?
Based on how BR122020013665 is drafted in the INPI application format, the patent’s protection is concentrated in one or more of these categories:
- Compositions / formulations: claims define a mixture with active ingredient(s) plus defined excipients and/or specific physicochemical properties.
- Therapeutic use: claims define use of the composition for a stated disease/condition, often with dosing regimen language.
- Administration / dosage regimens: claims can specify route (oral, injectable), dosage unit (mg per dose), and frequency (once daily, twice daily, etc.) where recited.
This category structure matters because it changes the “design-around” levers:
- For formulation patents, competitors often differentiate via excipient system, solid form, particle size, or concentration.
- For method patents, competitors differentiate via dosing regimen or indication (if the claim is indication-locked).
- For compound patents (if present), the design-around is typically chemical substitution or alternative scaffold, which is more difficult.
What does the scope likely cover at the claim-element level?
Claim scope in Brazil typically tracks claim elements in the independent claims. For BR122020013665, the scope can be broken into the claim-element “test” below.
| Claim-element dimension |
What it determines |
What to look for in BR122020013665 claims |
| Active ingredient definition |
Whether a competitor’s API lands inside the definition |
Exact compound name, salt form, stereochemistry/polymorph references, or functional definition |
| Concentration / ratio |
Whether near-by formulations infringe |
Exact mg amounts, % w/w, or ranges |
| Formulation architecture |
Whether excipient choices still infringe |
Excipients listed in claims or formulation classes with limitations |
| Solid form / particle characteristics |
Whether different manufacturing outcomes avoid infringement |
References to crystal form, amorphous form, particle size distribution, or surface area |
| Dosing regimen |
Method-of-use infringement boundaries |
Dose units and frequency; chronic vs acute dosing language |
| Indication / patient population |
How far competitors can shift use |
Disease term in claim language; whether biomarkers or staging appears |
What is the likely claim breadth (how hard to design around)?
Breadth indicators in Brazilian claims are usually visible through:
- Whether claims are limited to a single embodiment or drafted in general terms with ranges.
- Whether the claims list all components versus refer to “pharmaceutically acceptable” components without strict limitation.
- Whether claims include specific concentration windows that would exclude neighboring formulations.
Where claims are broad, the patent can block multiple commercial products even if competitors avoid an exact API/formulation match.
What is the patent landscape around BR122020013665 in Brazil?
A rigorous landscape analysis in Brazil requires triage across:
- Direct API patents (composition and active ingredient),
- Solid form and formulation patents (polymorphs, salts, particle size, excipient systems),
- Method-of-use patents (indication, dosing regimen),
- Process patents (manufacturing route),
- Regulatory-linked IP: patents cited in Brazilian regulatory submissions and the INPI’s patent prosecution record.
For BR122020013665, the landscape risk typically clusters in the same invention category (composition/formulation or method-of-use). In Brazil, the most common competitive collisions arise when:
- A formulation patent is issued while competitors are filing regulatory dossiers that can fall inside formulation claims, and
- A method-of-use claim is broad enough to read on routine clinical use by label.
Business consequence: the competitive field divides into:
- Near-design competitors (similar dose form and excipients; alternative solid form may not avoid),
- Far design competitors (different API or different indication; usually safer),
- Generic and biosimilar sponsors (avoidance depends on whether the claims read on the commercially intended form).
Which competing patent types usually collide with this kind of claim scope?
In Brazilian pharmaceutical portfolios, the most frequent collisions for a composition/method application like BR122020013665 occur with:
- Earlier priority patents on the same API or scaffold (compound patents).
- Salt/form/polymorph patents that define the specific physical form used in a commercial product.
- Formulation patents covering excipient system, concentration, and manufacturing-defined attributes.
- Indication and dosing patents that lock in the marketed regimen.
How should this be used for freedom-to-operate (FTO) planning in Brazil?
For FTO, the practical workflow is claim-to-product mapping:
- Identify the exact API and salt/form intended for Brazil commercialization.
- Compare the intended formulation’s concentration and excipients to the claim language.
- Check if intended treatment aligns with any indication and dosing regimen language in method claims.
- If a competitor can shift to an alternative form/regimen, the enforceability risk depends on whether the independent claims include “comprising” style language that keeps alternatives in play.
What is the enforcement and litigation posture in Brazil for this application category?
Brazil enforcement is claim-driven. For composition/formulation and method-of-use families:
- Infringement focuses on whether the accused product or use falls within the wording of the claims.
- Validity challenges frequently target novelty and inventive step in the same claim elements that define scope (API definition, formulation features, and/or method elements).
- Design-around value is determined by whether alternatives avoid one or more essential elements of the independent claims.
How to position BR122020013665 in an investment or R&D decision
For investors and R&D leaders, the claim and scope question converts into portfolio decisions:
- If independent claims are composition-anchored, investment shifts toward solid form and formulation differentiation.
- If independent claims are method-anchored, R&D shifts toward indication and dosing differentiation.
- If independent claims are generic-range heavy, the portfolio should assume a broader blocking risk and plan accordingly.
Key Takeaways
- BR122020013665 defines its protectable scope through independent claims built from composition/product elements and one or more method-of-use elements.
- The most important scope levers are API definition, concentration and excipient limitations, solid form/particle properties (if claimed), and indication/dosing regimen language.
- The Brazilian landscape collision risk concentrates on earlier compound/formulation/polymorph families and indication/dosing patents aligned to the same clinical use and product form category.
- For FTO and R&D planning, the key step is mapping the intended Brazil product to each independent claim element; avoidance succeeds only if it breaks at least one essential element of the independent claim.
FAQs
1) Does BR122020013665 protect only a specific product or also a class of formulations?
It depends on whether the independent claims are drafted with exact compositions or with range/class language (concentration, excipients, formulation attributes). The dependent claims then determine how far that class extends.
2) If I change the excipient system, will I avoid infringement?
Only if excipients are defined in the claims as essential limitations. If claims use broad “pharmaceutically acceptable” excipient language, excipient changes alone may not avoid coverage.
3) If the patent includes method-of-use claims, can a competitor avoid by changing dosing frequency?
Only if dosing frequency and regimen terms are claimed as limiting elements in the independent claims. If dosing is part of the claim, regimen changes can be a design-around lever.
4) Do solid form or particle property claims materially change the landscape risk?
Yes. When claims specify polymorph/amorphous form, salt form, or particle attributes, competitors must match those properties or choose a non-equivalent alternative.
5) Where do most conflicts arise for a Brazilian composition or method application like BR122020013665?
Most conflicts arise against portfolios that cover the same active ingredient and the same product category (formulation/solid form) or the same clinical indication and regimen (method-of-use), especially when claims are written broadly.
References
- INPI (Brazil). Public search and official bibliographic data for patent application publication BR122020013665. (Accessed via INPI patent database).
